Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

“Arcturus is actively engaged with the U.S. government to prepare for the next pandemic, and clearance to proceed into the clinic with our STARR® self-amplifying mRNA technology is a key step in this ...

The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

The detection of lumpy skin disease in Japan could be the game changer that prompts far greater financial investment into ...

Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating on October 28. Joseph Stringer has ...

Production tips from Crystal Bio, TriLink Biotechnologies, Ginkgo Bioworks, Quantoom Biosciences, and Parexel.

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older – ...

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in ...